Bristol-Myers Squibb has a new clinical research collaboration with Janssen Biotech, Inc. to evaluate the combination of BMS’ Immuno-Oncology (I-O) agent Opdivo and Janssen’s CD38-directed cytolytic antibody Darzalex in Phase Ib/II trials in multiple myeloma and solid tumors including non-small cell lung cancer, pancreatic cancer, colorectal cancer (CRC), triple negative breast cancer and head and neck cancer. Opdivois a human antibody designed to alleviate immune suppression. Darzalex is a c...